Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Sacituzumab tirumotecan |
| Synonyms | |
| Therapy Description |
Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to a topoisomerase I inhibitor, which delivers the drug to TROP2-expressing tumor cells, potentially resulting in antitumor activity (PMID: 41276258, Cancer Res (2024) 84 (7_Supplement): CT038). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Sacituzumab tirumotecan | SKB 264|SKB-264|ADC SKB264|MK-2870|MK 2870|MK2870|SKB264 | TROP2 Antibody 19 | Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody that targets trophoblast cell surface protein 2 (TROP2) linked to a topoisomerase I inhibitor, which delivers the drug to TROP2-expressing tumor cells, potentially resulting in antitumor activity (PMID: 41276258, Cancer Res (2024) 84 (7_Supplement): CT038). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06074588 | Phase III | Docetaxel Sacituzumab tirumotecan Pemetrexed Disodium | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Active, not recruiting | USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 11 |
| NCT06132958 | Phase III | Paclitaxel Doxorubicin Nab-paclitaxel Sacituzumab tirumotecan | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (TroFuse-005) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT06637423 | Phase Ib/II | Sacituzumab tirumotecan | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (TroFuse-027) | Recruiting | USA | NLD | GBR | FRA | ESP | CAN | 0 |
| NCT06952504 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Sacituzumab tirumotecan Carboplatin + Docetaxel + Pembrolizumab Pembrolizumab + Sacituzumab tirumotecan | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) (TroFuse-033) | Recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
| NCT06305754 | Phase III | Carboplatin + Pemetrexed Disodium Sacituzumab tirumotecan | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | Active, not recruiting | USA | TUR | SWE | POL | ITA | FRA | ESP | CAN | ARG | 10 |
| NCT06841354 | Phase III | Carboplatin + Gemcitabine Carboplatin + Nab-paclitaxel Pembrolizumab + Sacituzumab tirumotecan Sacituzumab tirumotecan Carboplatin + Paclitaxel | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Recruiting | USA | TUR | ROU | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 12 |
| NCT07458113 | Phase II | Sacituzumab tirumotecan | Sac-TMT for Active TNBC Brain Metastases (BERLIN) | Not yet recruiting | USA | 0 |
| NCT07511023 | Phase II | Sacituzumab tirumotecan | Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum | Not yet recruiting | USA | 0 |
| NCT04152499 | Phase Ib/II | Sacituzumab tirumotecan | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Active, not recruiting | USA | TUR | CAN | 3 |
| NCT06824467 | Phase III | Sacituzumab tirumotecan Bevacizumab + Sacituzumab tirumotecan Bevacizumab | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | Recruiting | USA | ROU | POL | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
| NCT06356311 | Phase III | Trifluridine-tipiracil hydrochloride Irinotecan Paclitaxel Docetaxel Sacituzumab tirumotecan | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015) | Active, not recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | 11 |
| NCT07419295 | Phase III | Sacituzumab tirumotecan Docetaxel Vinflunine Paclitaxel | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) (TroFuse-031) | Recruiting | USA | SWE | NLD | ITA | ISR | GRC | FRA | ESP | CAN | BRA | BEL | AUS | ARG | 2 |
| NCT07639086 | Phase II | Sacituzumab tirumotecan | Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy (STOP-NEPC) | Not yet recruiting | USA | 0 |
| NCT06428409 | Phase Ib/II | Cisplatin + Pembrolizumab + Sacituzumab tirumotecan Fluorouracil + Leucovorin + Sacituzumab tirumotecan Sacituzumab tirumotecan | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | Recruiting | USA | TUR | ITA | GBR | ESP | CHE | CAN | AUS | 5 |
| NCT06459180 | Phase III | Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Topotecan Sacituzumab tirumotecan | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
| NCT05816252 | Phase II | Osimertinib + Sacituzumab tirumotecan Carboplatin + Sacituzumab tirumotecan Carboplatin + Pembrolizumab + Sacituzumab tirumotecan Pembrolizumab + Sacituzumab tirumotecan Sacituzumab tirumotecan | A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | Active, not recruiting | TUR | ROU | ESP | 3 |
CKB BOOST